Phio Pharmaceuticals Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phio Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Phio Pharmaceuticals stock.
View analyst ratings for Phio Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Phio Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Phio Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Phio Pharmaceuticals saw a increase in short interest in the month of May. As of May 14th, there was short interest totaling 1,330,000 shares, an increase of 100.8% from the April 29th total of 662,200 shares. Based on an average daily volume of 1,000,000 shares, the short-interest ratio is currently 1.3 days. Currently, 10.0% of the company's stock are sold short.
View Phio Pharmaceuticals' Short Interest.

Phio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Phio Pharmaceuticals.

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) announced its quarterly earnings results on Thursday, March, 25th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.42) by $0.01.
View Phio Pharmaceuticals' earnings history.

Phio Pharmaceuticals' stock was trading at $2.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PHIO shares have decreased by 20.9% and is now trading at $2.19.
View which stocks have been most impacted by COVID-19.

1 analysts have issued 12 month target prices for Phio Pharmaceuticals' shares. Their forecasts range from $6.00 to $6.00. On average, they expect Phio Pharmaceuticals' stock price to reach $6.00 in the next year. This suggests a possible upside of 174.0% from the stock's current price.
View analysts' price targets for Phio Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Phio Pharmaceuticals include Galecto (GLTO), Evofem Biosciences (EVFM), Lipocine (LPCN), Agile Therapeutics (AGRX), Lotus Pharmaceuticals (LTUS), Anixa Biosciences (ANIX), Yumanity Therapeutics (YMTX), Longboard Pharmaceuticals (LBPH), Orgenesis (ORGS), Acasti Pharma (ACST), Processa Pharmaceuticals (PCSA), Aileron Therapeutics (ALRN), Onconova Therapeutics (ONTX), Eledon Pharmaceuticals (ELDN) and Celsion (CLSN).
View all of PHIO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include DURECT (DRRX), CymaBay Therapeutics (CBAY), Ocugen (OCGN), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Boxlight (BOXL), Evofem Biosciences (EVFM), Fulcrum Therapeutics (FULC), Jaguar Health (JAGX) and Milestone Pharmaceuticals (MIST).

Phio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHIO."

Phio Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include GSA Capital Partners LLP (0.98%), Geode Capital Management LLC (0.65%), Dimensional Fund Advisors LP (0.26%) and Virtu Financial LLC (0.11%). Company insiders that own Phio Pharmaceuticals stock include Gerrit Dispersyn and Robert L Ferrara.
View institutional ownership trends for Phio Pharmaceuticals.

PHIO stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, GSA Capital Partners LLP, Virtu Financial LLC, and Dimensional Fund Advisors LP. Company insiders that have bought Phio Pharmaceuticals stock in the last two years include Gerrit Dispersyn, and Robert L Ferrara.
View insider buying and selling activity for Phio Pharmaceuticals or or view top insider-buying stocks.

Shares of PHIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PHIO stock can currently be purchased for approximately $2.19.

Phio Pharmaceuticals has a market capitalization of $29.64 million and generates $20,000.00 in revenue each year. The company earns $-8,790,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis.

Phio Pharmaceuticals employs 10 workers across the globe.

The official website for Phio Pharmaceuticals is phiopharma.com.

Phio Pharmaceuticals is headquartered at 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752.

Phio Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The company can be reached via phone at 508-767-3861 or via email at [email protected]